Substrate transport limits phenylalanine ammonia-lyase activity in engineered Lacticaseibacillus rhamnosus GG

This study demonstrates that while *Lacticaseibacillus rhamnosus* GG is the most effective host for expressing therapeutic phenylalanine ammonia-lyase, its activity is primarily limited by substrate transport, which can be significantly enhanced (3–4-fold) through the expression of heterologous transporters rather than chemical surfactant treatment.

The Gist

The Big Picture: A "Living Pill" for a Rare Condition

Imagine a rare condition called Phenylketonuria (PKU). People with PKU have a broken "filter" in their bodies that usually cleans out a specific amino acid called phenylalanine (found in protein). Because their filter is broken, this amino acid builds up like trash in a room, eventually causing brain damage and other serious health issues.

The current treatment is like a strict diet where you can't eat almost any protein, which is hard and expensive. There is also a medicine (an enzyme) that acts like a "garbage collector" to break down the phenylalanine, but it has to be injected under the skin every day, which hurts and can cause allergic reactions.

The Goal: The scientists in this paper wanted to create a "living pill." Instead of injecting a drug, they wanted to engineer friendly bacteria (probiotics) that live in your gut to act as the garbage collector. These bacteria would eat the phenylalanine as you digest your food, turning it into harmless waste before it can hurt you.

---

The Experiment: Finding the Best "Garbage Truck"

The team tried to turn three different types of friendly bacteria (all from the "Lactic Acid" family, the same family found in yogurt) into these garbage trucks. They gave the bacteria a set of instructions (a gene) to make a special enzyme called PAL that eats phenylalanine.

The Contenders:

1. LGG (Lacticaseibacillus rhamnosus GG)
2. Ll (Lactococcus lactis)
3. Lp (Lactiplantibacillus plantarum)

The Result:
They found that LGG was the best driver. Even though the other bacteria made more of the enzyme (the garbage collector), LGG actually did the job of cleaning up the phenylalanine the fastest. It turned out that just having the tool isn't enough; you need the right tool for the specific job.

---

The Problem: The "Locked Door"

Here is the catch: The bacteria are like little houses with thick walls. The enzyme (PAL) lives inside the house, but the trash (phenylalanine) is outside. For the enzyme to work, the trash has to get inside the house.

The scientists realized the bacteria were struggling because the "door" to the house was too small or locked. The trash couldn't get in fast enough for the enzyme to do its job. This is called a transport limitation.

They tried two different ways to fix this "locked door" problem:

Attempt 1: The "Soap" Strategy (Surfactants)

• The Idea: Imagine the bacteria's wall is a sticky mesh. The scientists tried washing the bacteria with different types of "soap" (chemicals like Tween 20 or SDS) to loosen the mesh and make the door wider, hoping the trash would rush in.
• The Result: It didn't work. The soap didn't help the phenylalanine get inside. It's like trying to force a heavy box through a door by scrubbing the doorframe with soap; the door is still too small for the box.

Attempt 2: The "Special Delivery" Strategy (Transporters)

• The Idea: Instead of forcing the door open, they decided to build a special delivery ramp. They added a new gene to the bacteria that acts like a dedicated elevator or conveyor belt specifically designed to carry phenylalanine inside.
• The Result: It worked perfectly! By adding these "conveyor belts," the bacteria became 3 to 4 times more efficient at cleaning up the phenylalanine. The trash could finally get to the enzyme quickly.

---

The Takeaway

This study is a major step forward in making "living pills" a reality for people with PKU.

1. Pick the right host: Not all friendly bacteria are equal. LGG was the best choice for this specific job.
2. Don't just build the engine, build the fuel line: Making the enzyme isn't enough. You have to make sure the "fuel" (phenylalanine) can actually get to the enzyme.
3. The Solution: Adding a specific "transporter" (a delivery ramp) is a much better way to boost the bacteria's performance than trying to poke holes in their walls with soap.

In short: The scientists figured out how to turn a friendly gut bacteria into a highly efficient, living factory that can clean up a dangerous chemical in our bodies, potentially replacing painful daily injections with a simple probiotic supplement.

Technical Summary

1. Problem Statement

Phenylketonuria (PKU) is a metabolic disorder caused by a deficiency in phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine (Phe). While dietary restriction is the standard treatment, it is difficult to maintain. Enzyme replacement therapy using Phenylalanine Ammonia-Lyase (PAL) offers an alternative by converting Phe into trans-cinnamic acid (tCA).

• Current Limitations: The only FDA-approved PAL therapy (Pegvaliase) requires daily subcutaneous injections, posing risks of anaphylaxis and immune reactions.
• The Opportunity: Oral delivery of PAL via engineered probiotics (Live Biotherapeutic Products, or LBPs) could provide a safer, non-invasive alternative.
• The Specific Challenge: Whole-cell biocatalysts often suffer from low reaction rates due to mass transfer limitations. The bacterial cell wall and membrane restrict the uptake of the substrate (Phe) and the release of the product (tCA), preventing the intracellular enzyme from operating at full capacity. There is a lack of systematic comparison of different Lactic Acid Bacteria (LAB) strains as hosts and a lack of data on strategies to overcome these transport barriers in this context.

2. Methodology

The study employed a multi-stage approach to identify the optimal host and optimize substrate transport:

• Host Selection: Three GRAS (Generally Recognized As Safe) LAB strains were selected as expression hosts:
  1. Lacticaseibacillus rhamnosus GG (LGG)
  2. Lactococcus lactis MG1363 (Ll)
  3. Lactiplantibacillus plantarum WCFS1 (Lp)
• Strain Engineering:
  • The gene for Anabaena variabilis PAL (AvPAL*), codon-optimized for E. coli, was cloned into a broad-host-range plasmid (pSIP411-derived) under a constitutive synthetic promoter (P27).
  • Strains were transformed, and protein expression was verified via Western blot.
• Activity Assay:
  • Whole-cell PAL activity was measured by incubating cells with 25 mM L-Phe.
  • Reaction progress was monitored by measuring the absorbance of the product, tCA, at 290 nm.
  • Activity was normalized by cell density (OD600).
• Optimization Strategies:
  1. Chemical Permeabilization: LGG strains were treated with varying concentrations of surfactants (Tween 20, Triton X-100, and SDS) to decongest the cell wall and improve substrate diffusion.
  2. Heterologous Transporter Expression: Based on homology to the E. coli AroP transporter, putative Phe transporters were identified in Gram-positive bacteria (including L. rhamnosus, L. reuteri, and L. seeligeri) and the characterized FYWP protein from L. lactis. These were expressed from a pAMβ1-based vector under promoter P31 and co-expressed with AvPAL* in LGG.

3. Key Contributions

• Systematic Host Comparison: The study provides the first direct comparison of LGG, L. lactis, and L. plantarum as platforms for AvPAL* expression.
• Identification of Transport Bottleneck: The research definitively demonstrates that substrate (Phe) uptake, rather than enzyme expression levels, is the primary limiting factor for whole-cell PAL activity in these probiotics.
• Validation of Transporter Strategy: The study successfully proves that co-expressing heterologous amino acid transporters can significantly overcome mass transfer limitations in LAB, whereas chemical permeabilization does not.

4. Results

• Host Performance:
  • LGG exhibited the highest normalized PAL activity, followed by L. lactis, with L. plantarum showing the lowest.
  • Expression vs. Activity Paradox: Western blots revealed that L. lactis actually produced the highest amount of AvPAL* protein. However, this did not translate to higher activity, likely due to protein misfolding or failure to form the essential MIO (4-methylideneimidazole-5-one) catalytic adduct. In contrast, LGG showed lower protein levels but the highest functional activity.
• Surfactant Treatment:
  • Treatment with Tween 20, Triton X-100, and SDS at various concentrations failed to improve PAL activity.
  • Interpretation: While surfactants may aid sugar uptake in other contexts, they were ineffective for amino acid transport in this system, possibly due to cell toxicity or the specific nature of Phe transport mechanisms.
• Transporter Co-expression:
  • Co-expression of heterologous transporters (including the L. rhamnosus WP_014569403.1 and L. lactis FYWP) resulted in a 3–4 fold increase in whole-cell PAL activity compared to controls.
  • This confirms that Phe transport is the rate-limiting step. Even at relatively low enzyme expression levels, increasing substrate availability significantly boosted the reaction rate.

5. Significance

This work represents a critical step toward the clinical development of oral probiotic therapies for PKU.

• Platform Optimization: It identifies L. rhamnosus GG as the superior chassis for AvPAL* expression among the tested LABs.
• Mechanistic Insight: It shifts the focus of optimization from simply increasing enzyme expression to engineering substrate transport. This is a crucial design principle for future whole-cell biocatalysts.
• Therapeutic Potential: By demonstrating that transporter engineering can overcome mass transfer barriers without the need for harsh chemical treatments, the study validates a scalable and safe strategy for enhancing the efficacy of live biotherapeutic products (LBPs) for metabolic disorders.

In conclusion, the paper establishes that while LAB are viable hosts for PAL, their therapeutic potential is currently capped by substrate uptake. The solution lies not in chemical permeabilization, but in the genetic engineering of specific transporters to facilitate Phe entry into the cell.